Perampanel - Eisai
Alternative Names: E-2007; ER-155055-90; FYCOMPA; FycompaLatest Information Update: 28 Feb 2024
At a glance
- Originator Eisai Co Ltd
- Developer Eisai Co Ltd; ESTEVE
- Class Analgesics; Antiepileptic drugs; Nitriles; Pyridines; Pyridones; Small molecules
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Partial epilepsies; Tonic-clonic epilepsy
- Registered Epilepsy
- Phase III Seizures
- Discontinued Migraine; Multiple sclerosis; Neuropathic pain; Parkinson's disease
Most Recent Events
- 31 Jan 2024 Registered for Epilepsy in Japan (IV), before January 2024
- 16 May 2023 Eisai completes a phase I/II trial in Seizures (Prevention) in USA (PO, Tablet) (NCT04497142)
- 25 Apr 2023 Eisai completes a phase II trial in Epilepsy (Adjunctive treatment, In children, In infants) in Latvia, USA (PO) (EudraCT2013-005391-17) (NCT02914314)